ELAB: Gunggung utang perusahaan Elevai Labs

Elevai Labs Inc. (ELAB) has established high technological barriers through patents on stem cell therapy methods and clinical testing expenditures. The company develops innovative exosome-based products for dermatologists, targeting the growing anti-aging care segment. Serum production is outsourced to reliable CMOs, eliminating operational risks. This price action chart on GURU.Markets shows that the separate_debt metric is 0.02.

Elevai Labs Inc. - Utang perusahaan ELAB (periode 21.02.2024 - 28.10.2026)

Rincian analitis lan laporan data perusahaan Elevai Labs (ELAB)

- rega lan prakiraan konsensus rega:

Bagan owah-owahan rega Elevai Corp|ELAB - Prakiraan konsensus analis

- data kapitalisasi pasar:

Kapitalisasi pasar Elevai Skincare|ELAB - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi Saham Elevai Labs|ELAB - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih elevaiskincare.com|ELAB - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Elevai Labs Inc.|ELAB - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Elevai Labs Inc|ELAB - Utang perusahaan|Utang-utang marang aset resik Elevai Skincare|ELAB - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Elevai Labs

Ringkesan analisis perusahaan:Elevai Corp ELAB

Elevai Labs Inc. (ELAB) investments in recruiting highly qualified biochemists and developing regenerative technologies require significant capital, making debt load control a critical factor for sustainability. The dynamics of total credit obligations reflect the aggregate of all the company's borrowed funds, allowing investors to assess the balance between aggressive business scaling and the risk of default should the cost of resources change.

Perusahaan pesaing